The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)

PHASE2CompletedINTERVENTIONAL
Enrollment

167

Participants

Timeline

Start Date

June 9, 2017

Primary Completion Date

January 9, 2019

Study Completion Date

February 9, 2019

Conditions
Nonproliferative Diabetic Retinopathy
Interventions
DRUG

AKB-9778

Subcutaneous AKB-9778 15mg

DRUG

Placebo

Subcutaneous Placebo

Trial Locations (53)

11967

Island Retina, Shirley

13224

Retina Vitreous Surgeons of Central New York, Syracuse

18017

Mid-Atlantic Retina, Bethlehem

21740

Cumberland Valley Retina Consultants PC, Hagerstown

30060

Georgia Retina, Marietta

30909

Southeast Retina Center, Augusta

32503

Retina Specialty Institute, Pensacola

33064

Rand Eye Institute, Deerfield Beach

33805

Center for Retina and Macular Disease, Lakeland

37203

Tennessee Retina, Nashville

40509

Retina Associates of Kentucky, Lexington

44122

Retina Associates of Cleveland, Beachwood

44130

Retina Associates of Cleveland, Middleburg Heights

44505

Retina Associates of Cleveland, Youngstown

45242

Cincinnati Eye Institute, Cincinnati

46290

Midwest Eye Institute, Indianapolis

49202

Specialty Eye Institute, Jackson

50266

Wolfe Eye Clinic, West Des Moines

60304

Illinois Retina Associates, Oak Park

60452

University Retina, Oak Forest

67226

Central Plains Eye MDs, Wichita

73013

Retina Vitreous Center, Edmond

76012

Texas Retina Associates, Arlington

76104

Texas Retina Associates, Fort Worth

77025

Retina and Vitreous of Texas, Houston

77030

Retina Consultants of Houston, Houston

77384

Retina Consultants of Houston, The Woodlands

78240

Medical Center Ophthalmology Associates, San Antonio

78503

Valley Retina Institute, McAllen

78550

Valley Retina Institute, Harlingen

78705

Austin Retina Associates, Austin

Retina Research Center, Austin

79606

Retina Research Institute of Texas, Abilene

80401

Colorado Retina Associates, Golden

80909

Retina Consultants of Southern Colorado, Colorado Springs

85021

Arizona Retina and Vitreous Consultants, Phoenix

85053

Retinal Research Institute, Phoenix

87109

Eye Associates of New Mexico, Albuquerque

89502

Sierra Eye Associates, Reno

90211

Retina Vitreous Associates Medical Group, Beverly Hills

91007

Retina Institute of California, Arcadia

92056

Ophthalmic Clinical Trials San Diego, Oceanside

92835

Retina Consultants of Orange County, Fullerton

93103

California Retina Consultants, Santa Barbara

93309

California Retina Consultants, Bakersfield

93454

California Retina Consultants, Santa Maria

94303

Stanford, Palo Alto

99204

Spokane Eye Clinical Research, Spokane

212876

Johns Hopkins University School of Medicine, Baltimore

02114

Opthalmic Consultants of Boston, Boston

07003

Retina Center of New Jersey, Bloomfield

08820

New Jersey Retina, Edison

08225

Retinal and Ophthalmic Consultants P.C., Northfield

Sponsors
All Listed Sponsors
lead

EyePoint Pharmaceuticals, Inc.

INDUSTRY

NCT03197870 - The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR) | Biotech Hunter | Biotech Hunter